Article Text

PDF
Prescribing in Parkinson's disease: a story of hope and adverse events
  1. Paul Morrish
  1. Correspondence to Paul Morrish, Department of Neurology, Gloucestershire Hospitals NHS, Beacon House, Great Western Road, Gloucester GL1 3NN, UK; paul.morrish{at}glos.nhs.uk

Abstract

A review of National Health Service spending in England on prescription drugs used in Parkinsonism over the last 10 years shows that spending has risen rapidly and that newly introduced drugs are quickly and expensively adopted. This paper explores the gains and costs of such prescribing.

Statistics from Altmetric.com

Footnotes

  • Contributors PM retrieved and analysed data, wrote and submitted the manuscript.

  • Competing interests The author has received no lecture fees or honoraria directly from the pharmaceutical industry over the last 6 years though, on five occasions over the same period, has received a speaker fee or honorarium from a sponsored educational meeting and has received hospitality at other sponsored meetings. He also sits, unpaid, on the steering committee of the PDMED trial.

  • Provenance and peer review Not commissioned; externally peer reviewed. This paper was reviewed by Paul Worth, Norwich, UK.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editors' choice
    Phil Smith Geraint Fuller